Gilead Sciences' hepatitis C drugs Sovaldi and Harvoni are the poster children for out-of-control drug costs, but competition from AbbVie's drug may place downward pressure on these prices.
Gilead Sciences’ hepatitis C drugs Sovaldi and Harvoni are the poster children for out-of-control drug costs, but increased competition may see some downward pressure of costs.
On Monday, Express Scripts updated its formulary to expand access to AbbVie’s new breakthrough treatment for the hepatitis C virus. Viekira Pak was just approved by the FDA on December 19 and determined to be at least clinically equivalent to Sovaldi and Harvoni. Starting January 1, 2015, Viekira Pak will be the exclusive option for genotype 1 hepatitis C, according to Express scripts.
“Pharmaceutical innovation must be rewarded based on the value it brings to patients and payers,” Steve Miller, MD, senior vice president and chief medical officer of Express Scripts, said in a statement. “This agreement marks a fundamental change in how sustainable access and affordability will be delivered to hepatitis C patients."
Viekira Pak will be available for all patients regardless of symptoms or disease. Previously, many US payers were only covering pricier hepatitis C medications for patients experiencing stage 3 or 4 liver disease.
"If the specialty drug trend continues to increase by double digit percentages, payers will be forced to implement even more narrow management tools, thus limiting the number of patients who can afford to receive the drug therapy," said Paula Jakub, chief executive officer/executive vice president of American Foreign Service Protective Association, an Express Scripts client. "It only makes sense for manufacturers to work with payers on pricing decisions. We are delighted to be a partner in this relationship to explore new approaches for the right person to receive the right drug at the right time."
However, the drug is not a huge discount to Sovaldi, which costs $84,000 for a 12-week course of therapy. Harvoni costs $94,500 for 12 weeks. AbbVie has set the price for Viekira Pak at $83,319 for the same length of therapy. However, The New York Times suspects that Express Scripts and AbbVie were able to negotiate a more favorable price with discounts that will help hold down healthcare costs for employers using Express Scripts.
"We want all hepatitis C patients to receive the best care our healthcare system can deliver, but that option simply wasn't possible until today," said Dr Miller.
Research Shows Prior Authorization Denials Delay Critical Immunology Care
May 10th 2024Results featured at the Academy of Managed Care Pharmacy 2024 annual meeting revealed a pattern of prior authorization rejections that could delay necessary therapeutic treatments for various patient groups.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Traditional Medicare Supplemental Insurance and the Rise of Medicare Advantage
May 7th 2024Rising Medicare Advantage enrollment occurred alongside declines in enrollment in traditional Medicare with employer-sponsored supplemental coverage and traditional Medicare without supplemental coverage.
Read More
The Senate Finance Committee has introduced bipartisan legislation that proposes using Medicaid and Medicare programs to help prevent and reduce generic drug shortages; US indicators for COVID-19, flu, and respiratory syncytial virus (RSV) declined further last week; findings from a recent study reveal growing disparities in child death rates across racial and ethnic groups.
Read More